Search

Your search keyword '"Izzi, T"' showing total 93 results
Start Over Author "Izzi, T"
93 results on '"Izzi, T"'

4. Infusion of Fetal Liver Cells in Aplastic Anemia

Author

Lucarelli, G., Izzi, T., Porcellini, A., Delfini, C., Heimpel, H., editor, Huhn, D., editor, Ruhenstroth-Bauer, G., editor, Heimpel, Hermann, editor, Gordon-Smith, Edward C., editor, Heit, Wolfgang, editor, and Kubanek, Bernhard, editor

Published
1979
Full Text
View/download PDF

5. Risk-oriented postremission strategies in adult acute lymphoblastic leukemia: prospective confirmation of anthracycline activity in standard-risk class and role of hematopoietic stem cell transplants in high-risk groups

Author

Bassan R, Pogliani E, Casula P, Rossi G, Fabris P, Morandi S, Lambertenghi-Deliliers G, Vespignani M, Lerede T, Rambaldi A, Borleri G, Spedini P, AGOSTINO CORTELEZZI, Izzi T, Coser P, Broccia G, Corneo G, and Barbui T

Subjects
Adult, Male, Adolescent, Cytarabine, Hematopoietic Stem Cell Transplantation, Antineoplastic Agents, Hematology, Middle Aged, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Disease-Free Survival, Methotrexate, Risk Factors, Antineoplastic Combined Chemotherapy Protocols, Humans, Transplantation, Homologous, Female, Idarubicin, Cyclophosphamide, Melphalan, Whole-Body Irradiation, Aged
Abstract

Although definite risk classes are well known, risk-adapted modulation of first-line therapy is seldom attempted in adult ALL. So, a prospective validation of the therapeutic efficacy of a protocol (or a component thereof) in specific risk groups is uncommon.From 1996-1999 a risk-oriented program (08/96) was evaluated in 102/121 unselected patients (median age 35 years, blast count 0-450 x 10(9)/l, 100 B(lin) (lineage), 21 T(lin)) responsive to induction therapy. The standard risk (SR) class was B(lin) CD10+ Ph- with blasts10 x 10(9)/l (prior studies: disease-free survival (DFS) rate 52% at five years with dose-intensive anthracycline-containing programs). The SR protocol was therefore anthracycline-rich (early consolidation cycles with total idarubicin 96 mg/m2), and comprised long-term maintenance. High-risk (HR) patients were eligible to the following three options: allogeneic hematopoietic stem cell transplantation (HSCT) from related family donor; short sequence with high-dose cyclophosphamide-cytarabine-methotrexate followed by melphalan/total body irradiation with autologous HSCT; or T(lin) ALL chemotherapy regimen inclusive of high-dose cytarabine and methotrexate.Treatment realization and three-year DFS rates according to risk class, HR subset and postremission treatment intensity were the following. SR group (n = 28): realization rate 93%, DFS 68.5%. HR group (n = 74): realization rate 80%, DFS 39% (P = 0.052 vs SR category). In HR group, three-year DFS rates by disease subtype were the following. B(lin) Ph- (n = 35) 43%; Ph+ (n = 19) 13% at 2.7 years (P = 0.006 vs other HR subtypes); T(lin) (n = 18) 59.5%. And DFS rates by treatment intensity were: allograft (n = 21) 40%; autograft (n = 28) 27%; shift to SR protocol (n = 13) 52% (P = ns vs allograft/autograft); T(lin) program (n = 10) 57%. Matched analyses of treatment protocols and disease subtypes suggested a possible therapeutic role of the autograft regimen in B(lin) Ph- ALL with a blast count25 x 10(9)/l, and of T(lin) protocol for T(lin) ALL. Comparisons with retrospective control cohorts were confirmatory of anthracycline activity in SR subclass.The intended strategy was applicable to the majority of study patients, confirming the value of anthracyclines in SR class and, preliminarily, the usefulness a T(lin)-specific treatment. Apart from the case of Ph+ ALL, the indications for high-dose procedures with HSCT remains largely undetermined in this study.

Published
2001
Full Text
View/download PDF

6. Will Molecular Biology Contribute to Refine Prognosis and to Select Treatment?

Author

Zaccaria, A, Martinelli, G, Buzzi, M, Farabegoli, P, Saglio, G, Guerrasio, A, Bernabei, P, Santini, V, Pellicci, P, Mencarelli, A, Coco, F, Diverio, D, Rambaldi, A, Santoro, A, Tura, S, Russo, D, Zuffa, E, Fanin, R, Patriarca, F, Fiacchini, M, Baccarani, M, Testoni, N, Zamagni, M, Montefusco, E, Alimena, G, Meloni, G, Mandelli, F, Damiani, D, Michieli, M, Criscuolo, D, Fowst, C, Holdener, E, Specchia, G, Liso, V, Morra, E, Bernasconi, C, Demilio, A, Battista, R, Ditucci, A, Broccia, G, Maiolino, I, Caronia, F, Luciano, L, Rotoli, B, Leoni, P, Danieli, G, Bodenizza, C, Carotenuto, M, Rotondo, S, Nosari, A, Decataldo, F, Montuoro, A, Delaurenzi, A, Camillo, S, Liberati, A, Grignani, F, Tabilio, A, Martelli, M, Barbui, T, Leoni, F, Ciolli, S, Ronca, F, Nobile, F, Paolino, F, Resegotti, L, Papineschi, F, Spremolla, G, Landolfi, R, Leone, G, Volpe, E, Mangoni, L, Rizzoli, V, Capucci, A, Izzi, T, Scapoli, G, Castoldi, G, Gentilini, I, Coser, P, Gallo, E, Pileri, A, Cantonetti, M, Papa, G, Dini, D, Morandi, S, Bianchini, E, Pinotti, G, Venco, A, Zagonel, V, Pinto, A, Capaldi, A, Giovannelli, E, Pizzuti, M, Ricciuti, F, Ambrosetti, A, Cajozzo, A, Lombardo, M, Torlontano, G, Delfini, C, Lucarelli, G, Girino, M, Ascari, E, Risso, M, Damasio, E, Martino, S, Pardini, S, Longinotti, M, Miraglia, E, Debiase, R, Nardelli, S, Galieni, P, Dispensa, E, Abbadessa, A, Bruzzese, L, Prossomariti, L, Cimino, R, Derosa, C, Gabbas, A, Francesco, S, Gallamini, A, Difrancesco, A, Quaglino, D, Musolino, C, Squadrito, G, Avanzini, P, Gobbi, F, Nuova, A, Emilia, R, Aglietta, M, Camaschella, C, Mazza, M, Guglielmo, P, Cacciola, E, and Monaco, M

Subjects
INTERFERON, CHRONIC MYELOID LEUKEMIA, Cancer Research, PROGNOSIS, biology, Settore MED/06 - Oncologia Medica, business.industry, MOLECULAR BIOLOGY, Breakpoint, Transcript analysis, Hematology, HindIII, Bioinformatics, Restriction site, Text mining, Oncology, Risk index, biology.protein, Medicine, In patient, business, Settore MED/15 - Malattie del Sangue, Southern blot
Abstract

The possible prognostic value of the position of the breakpoint within the M-BCR in patients with Phl+ CML is still being debated. We analyzed the DNA rearrangements and the transcript types of 244 patients and tried to correlate the data obtained with prognostic features, defined according to Sokal's risk index, and with chronic phase and/or survival duration. The exact location of the breakpoint, either 5' or 3' to the Hind III restriction site within the M-BCR was identified. Moreover, the exact M-BCR subregion was also identified. As a whole, 150 pts were rearranged in the 5' part and 94 in the 3' part of the M-BCR. No correlation was observed between the site of rearrangement on the one hand and the Sokal's prognostic index and survival, on the other. Transcript analysis was performed in 130 patients; 59 carried an a2b2 and 69 an a2b3 pattern. Two patients carried both transcripts. Of the patients rearranged in the 5' area, according to Southern blotting, 29.2% showed an a2b3 transcript. Therefore, R...

Published
1993
Full Text
View/download PDF

7. Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukemia: Influence of dose and stem cell source shows better outcome with rich marrow

Author

Gorin N.C., Labopin M., Rocha V., Arcese W., Beksac M., Gluckman E., Ringden O., Ruutu T., Reiffers J., Bandini G., Falda M., Zikos P., Willemze R., Frassoni F., Abecasis M., Abráhamová J., Afanassiev B.V., Aglietta M., Alabdulaaly A., Aleinikova O., Paolo Alessandrino E., Al Shemmari S.H., Amadori D., Amadori S., Amos T., Andolina M., Andreesen R., Angelucci E., Anhuf J., Arnold R., Arpaci F., Attal M., Azevedo W., Azim H.A., Baccarani M., Bacigalupo A., Barbui T., Bargetzi M., Barnard D.L., Bartsch H.H., Baruchel A., Battista C., Bay J.-O., Bayik M., Bazarbachi A., Beguin Y., López J.L.B., Benedek I., Benedetti F., Bengala C., Berrebi A., Besalduch J., Biesma D., Biron P., Björkholm M., Blaise D., Blesing N.E., Boasson M., Bobev D., Boccadoro M., Bolaman Z., Boogaerts M.A., Bordessoule D., Bosi A., Aida B.S., Bourhis J.H., Bourikas G., Bowen D.T., Bregni M., Bries G., Brinch L., Brittain D., Bron D., Brune M., Bullorsky E.O., Bunjes D., Burdach S., Burnett A.K., Buzyn A., Caballero D., Cagirgan S., Cahn J.-Y., Canepa C.O., Cao A., Carella A.M., Carrera F.D., Carret A.-S., Cascinu S., Castel V., Caswell M., Cavanna L., Cetto G.L., Chapuis B., Chasty R., Chen Y.-C., Chisesi T., Chopra R., Chybicka A., Clark R.E., Colombat P., Colovic M.D., Constenla-Figueiras M., Contreras M., Contu L., Cordonnier C., Cornelissen J.J., Cornish J., Coser P., Costa N., Coze C., Craddock C., Crown J., Culligan D.J., Danova M., Darbyshire P.J., Davies J.M., de Bock R., de Pablos Gallego J.M., De Prijck B., de Revel T., De Rossi G., De Souza C.A., Deb G., Degos L., Demuynck H., Dervenoulas I., Di Bartolomeo P., Di Renzo N., Diaz M.A., Diehl V., Diez-Martin J.L., Dincer S., Giorgio D., Dmoszynska A., Doelken G., Peter P.D., Dulley F., Easow J., Ebell W., Efremidis A., Ehninger G., Eichler H., Eimermacher H., Enno A., Errazquin L., Aguado J.E., Everaus H., Fagioli F., Fanin R., Fassas A., Fasth A., Faulkner L.B., Fauser A.A., Feldman L., Feremans W., Ferhanoglu B., Fernández M.N., Fernández-Ranada J.M., Ferrant A., Ferrara F., Finke J., Fischer A., Fischer J., Fitzsimons T., Floristan F., Forjaz de Lacerda J.M.F., Fossati-Bellani F., Fosser V., Franklin I., Freund M., Frickhofen N., Gabbas A., Gadner H., Gallamini A., Galvin M.C., López J.G., García-Conde J., Gaska T., Gastl G., Gedikoglu G., Ghavamzadeh A., Gianni A., Gibson B.E., Gil J.L., Gilleece M.H., Gisselbrecht C., Glass B., Gmür J., Göbel U., Goldman J.M., Goldstone A.H., San Miguel J.D.G., González-López M.-A., Grafakos S., Gramatzki M., Grañena A., Gratecos N., Gratwohl A., Greinix H.T., Gugliotta L., Guilhot F., Guimaraes J.E., Gülbas Z., Gulyuz O., Gurman G., Gutierrez M.M., Haas R., Hamladji R.-M., Hamon M.D., Hansen N.E., Harhalakis N., Harousseau J.L., Hartenstein R., Hartmann C.O., Hausmaninger H., Haznedar R., Heit W., Hellmann A., Herrmann R.P., Hertenstein B., Hess U., Hinterberger W., Ho A.D., Hoelzer D., Holowiecki J., Horst H.-A., Hossfeld D.K., Huebsch L., Hunter A.E., Iacopino P., Iannitto E., Indrák K., Iriondo A., Izzi T., Jackson G.L., Jacobs P., Jacobsen N., Janvier M., Jebavy L., Joensuu H., Joerg S., Jones F.G.C., Jouet J.P., Joyner M.V., Juliusson G., Jürgens H., Kalayoglu-Besisik S., Kalman N., Kalmanti M., Kansoy S., Kansu E., Kanz L., Karianakis G., Kernéis Y., Khalifeh O., Khomenko V., Kienast J., Killick S., Kirchner H.H., Klingebiel T., Knauf W., Koenigsmann M., Koistinen P., Koivunen E., Kolb H.-J., Kolbe K., Koller E., Komarnicki M., Koscielniak E., Kovacsovics T., Kowalczyk J.R., Koza V., Kozak T., Kugler J., Kuliczkowski K., Kvaloy S., Labar B., Laciura P., Palacios J.J.L., Lakota J., Lambertenghi D.G., Lange A., Lanza F., Isasti R.L., Lauria F., Le Moine F., Leblond V., Lelli G., Lenhoff S., Leon L.A., Leoncini-Franscini L., Leone G., Leoni P., Levis A., Leyvraz S., Liberati M., Link H., Linkesch W., Liso V., Lisukov I.A., Littlewood T., Ljungman P., Locatelli F., Losonczy H., Lotz J.-P., Ludwig H., Lukac J., Lutz D., Macchia P., Madrigal A., Maiolino A., Majolino I., Eloy-García J.M., Malesevic M., Mandelli F., Marc A., Marcus R., Marianska B., Markuljak I., Marsh J.C.W., Martelli M.F., Marti Tutusaus J.M., Martin S., Martin M., Martinelli G., Martínez-Rubio A.M., Martoni A., Maschan A., Maschmeyer G., Masszi T., Mazza P., McCann S., Meier C.R., Messina C., Mettivier V., Metzner B., Michallet M., Michieli M., Michon J., Milligan D.W., Milone J.H., Giuseppe G.M., Minigo H., Mistrik M., Moicean A.D., Monfardini S., Montserrat E., Moraleda Jimenez J.M., Morales-Lazaro A., Morandi S., Morra E., Mufti G.J., Musso M., Nagler A., Nalli G., Naparstek E., Narni F., Nenadov-Beck M., Neubauer A., Newland A.C., Niederwieser D., Niethammer D., Noens L.A., Nousiainen T., Novik A., Novitzky N., Occhini D., Odriozolas J., Ojanguren J.M., O’meara A., Onat H., Orchard K., Ortega J.J., Osieka R., Ossenkoppele G.J., Othman B., Ovali E., Ozcebe O.I., Ozerkan K., Ozturk A., Papatryfonos A., Parker J.E., Pastore M., Patrone F., Patton N., Pejin D., Peñarrubia M.J., Equiza E.P., Peschel C., Pession A., Pigaditou A., Pignon B., Pihkala U., Pimentel P., Pitini V., Podoltseva E., Pogliani E.M., Anna A.P., Porta F., Potter M., Powles R., Prentice G.H., Pretnar J., Ptushkin V., Quarta G., Reiter A., Remes K., Reykdal S., Santasusana J.M.R., Rifón J., Rio B., Rizzoli V., Robak T., Robinson A.J., Rodeghiero F., Rodríguez Fernández J.M., Rombos Y., Romeril K.R., Rosenmayr A., Rossi J.F., Rosti G., Rotoli B., Rowe J.M., Russell N.H., Ryzhak O., Rzepecki P., Saglio G., Salwender H., Samonigg H., Santoro A., Sanz M.A., Sayer H.G., Scanni A., Schaafsma M.R., Schaefer U.W., Schanz U., Schattenberg A., Schey S.A.M., Schlimok G., Schmoll H.-J., Schots R., Schouten H., Schwarer A.P., Schwerdtfeger R., Scimè R., Segel E., Seger R., Selleslag D., Serban M., Shamaa S., Shaw P.J., Siegert W., Siena S., Sierra J., Simonsson B., Singer C.R.J., Sirchia G., Skotnicki A.B., Slavin S., Snowden J., Sotto J.J., Tanyeli A., Tedeschi L., Tidefelt U., Tissot J.-D., Tobler A., Tomas J.F., Torres J.P., Torres G.A., Touraine J.-L., Trneny M., Uderzo C., Unal E., Unal A., Undar L., Urban C., Van den Berg H., van Marwijk K.M., Vellenga E., Venturini M., Verdonck L.F., Veys P., Vilardell J., Vinante O., Visani G., Vitek A., Vivancos P., Volpe E., Vora A., Vorlicek J., Vowels M., Vujic D., Wachowiak J., Wagner T., Wahlin A., Walewski J., Wandt H., Weissinger F., Wijermans P.W., Wiktor-Jedrzejczak W., Will A.M., Woell E., Wörmann B., Yaniv I., Yesilipek M.A., Yilmaz U., Yong A., Zachée P., Zambelli A., Zander A.R., Zintl F., Zoumbos N.C., Çukurova Üniversitesi, Maltepe Üniversitesi, and Ege Üniversitesi

Subjects
Myeloid, Male, Pathology, Time Factors, Graft vs Host Disease, Biochemistry, Gastroenterology, Blood cell, Bone Marrow, Child, Bone Marrow Transplantation, Leukemia, Remission Induction, Hematology, Middle Aged, Prognosis, Leukemia, Myeloid, Acute, ComputingMilieux_MANAGEMENTOFCOMPUTINGANDINFORMATIONSYSTEMS, medicine.anatomical_structure, Treatment Outcome, Child, Preschool, Female, Stem cell, InformationSystems_MISCELLANEOUS, Homologous, Adult, medicine.medical_specialty, Adolescent, Immunology, Acute, Disease-Free Survival, Internal medicine, medicine, Transplantation, Homologous, Humans, Preschool, Aged, Transplantation, business.industry, ComputerSystemsOrganization_COMPUTER-COMMUNICATIONNETWORKS, Cell Biology, medicine.disease, Peripheral blood, Histocompatibility, Multivariate Analysis, Stem Cell Transplantation, ComputingMethodologies_PATTERNRECOGNITION, Myelocytic leukemia, Bone marrow, business, Settore MED/15 - Malattie del Sangue
Abstract

PubMed ID: 12829583, Several studies have compared bone marrow (BM) and peripheral blood (PB) as stem cell sources in patients receiving allografts, but the cell doses infused have not been considered, especially for BM. Using the ALWP/EBMT registry, we retrospectively studied 881 adult patients with acute myelocytic leukemia (AML), who received a non-T-depleted allogeneic BM (n = 515) or mobilized PB (n = 366) standard transplant, in first remission (CR1), from an HLA-identical sibling, over a 5-year period from January 1994. The BM cell dose ranged from 0.17 to 29 × 10 8 /kg with a median of 2.7 × 10 8 /kg. The PB cell dose ranged from 0.02 to 77 × 10 8 /kg with a median of 9.3 × 10 8 /kg. The median dose for patients receiving BM (2.7 × 10 8 /kg) gave the greatest discrimination. In multivariate analyses, high-dose BM compared to PB was associated with lower transplant-related mortality (RR = 0.61; 95% CI, 0.39-0.98; P = .04), better leukemia-free survival (RR = 0.65; 95% CI, 0.46-0.91; P = .013), and better overall survival (RR = 0.64; 95% CI, 0.44-0. 92; P = .016). The present study in patients with AML receiving allografts in first remission indicates a better outcome with BM as compared to PB, when the dose of BM infused is rich. © 2003 by The American Society of Hematology.

Published
2003

8. Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukemia: Influence of dose and stem cell source shows better outcome with rich marrow

Author

Gorin, N.C. Labopin, M. Rocha, V. Arcese, W. Beksac, M. Gluckman, E. Ringden, O. Ruutu, T. Reiffers, J. Bandini, G. Falda, M. Zikos, P. Willemze, R. Frassoni, F. Abecasis, M. Abráhamová, J. Afanassiev, B.V. Aglietta, M. Alabdulaaly, A. Aleinikova, O. Paolo Alessandrino, E. Al Shemmari, S.H. Amadori, D. Amadori, S. Amos, T. Andolina, M. Andreesen, R. Angelucci, E. Anhuf, J. Arnold, R. Arpaci, F. Attal, M. Azevedo, W. Azim, H.A. Baccarani, M. Bacigalupo, A. Barbui, T. Bargetzi, M. Barnard, D.L. Bartsch, H.H. Baruchel, A. Battista, C. Bay, J.-O. Bayik, M. Bazarbachi, A. Beguin, Y. López, J.L.B. Benedek, I. Benedetti, F. Bengala, C. Berrebi, A. Besalduch, J. Biesma, D. Biron, P. Björkholm, M. Blaise, D. Blesing, N.E. Boasson, M. Bobev, D. Boccadoro, M. Bolaman, Z. Boogaerts, M.A. Bordessoule, D. Bosi, A. Aida, B.S. Bourhis, J.H. Bourikas, G. Bowen, D.T. Bregni, M. Bries, G. Brinch, L. Brittain, D. Bron, D. Brune, M. Bullorsky, E.O. Bunjes, D. Burdach, S. Burnett, A.K. Buzyn, A. Caballero, D. Cagirgan, S. Cahn, J.-Y. Canepa, C.O. Cao, A. Carella, A.M. Carrera, F.D. Carret, A.-S. Cascinu, S. Castel, V. Caswell, M. Cavanna, L. Cetto, G.L. Chapuis, B. Chasty, R. Chen, Y.-C. Chisesi, T. Chopra, R. Chybicka, A. Clark, R.E. Colombat, P. Colovic, M.D. Constenla-Figueiras, M. Contreras, M. Contu, L. Cordonnier, C. Cornelissen, J.J. Cornish, J. Coser, P. Costa, N. Coze, C. Craddock, C. Crown, J. Culligan, D.J. Danova, M. Darbyshire, P.J. Davies, J.M. de Bock, R. de Pablos Gallego, J.M. De Prijck, B. de Revel, T. De Rossi, G. De Souza, C.A. Deb, G. Degos, L. Demuynck, H. Dervenoulas, I. Di Bartolomeo, P. Di Renzo, N. Diaz, M.A. Diehl, V. Diez-Martin, J.L. Dincer, S. Giorgio, D. Dmoszynska, A. Doelken, G. Peter, P.D. Dulley, F. Easow, J. Ebell, W. Efremidis, A. Ehninger, G. Eichler, H. Eimermacher, H. Enno, A. Errazquin, L. Aguado, J.E. Everaus, H. Fagioli, F. Fanin, R. Fassas, A. Fasth, A. Faulkner, L.B. Fauser, A.A. Feldman, L. Feremans, W. Ferhanoglu, B. Fernández, M.N. Fernández-Ranada, J.M. Ferrant, A. Ferrara, F. Finke, J. Fischer, A. Fischer, J. Fitzsimons, T. Floristan, F. Forjaz de Lacerda, J.M.F. Fossati-Bellani, F. Fosser, V. Franklin, I. Freund, M. Frickhofen, N. Gabbas, A. Gadner, H. Gallamini, A. Galvin, M.C. López, J.G. García-Conde, J. Gaska, T. Gastl, G. Gedikoglu, G. Ghavamzadeh, A. Gianni, A. Gibson, B.E. Gil, J.L. Gilleece, M.H. Gisselbrecht, C. Glass, B. Gmür, J. Göbel, U. Goldman, J.M. Goldstone, A.H. San Miguel, J.D.G. González-López, M.-A. Grafakos, S. Gramatzki, M. Grañena, A. Gratecos, N. Gratwohl, A. Greinix, H.T. Gugliotta, L. Guilhot, F. Guimaraes, J.E. Gülbas, Z. Gulyuz, O. Gurman, G. Gutierrez, M.M. Haas, R. Hamladji, R.-M. Hamon, M.D. Hansen, N.E. Harhalakis, N. Harousseau, J.L. Hartenstein, R. Hartmann, C.O. Hausmaninger, H. Haznedar, R. Heit, W. Hellmann, A. Herrmann, R.P. Hertenstein, B. Hess, U. Hinterberger, W. Ho, A.D. Hoelzer, D. Holowiecki, J. Horst, H.-A. Hossfeld, D.K. Huebsch, L. Hunter, A.E. Iacopino, P. Iannitto, E. Indrák, K. Iriondo, A. Izzi, T. Jackson, G.L. Jacobs, P. Jacobsen, N. Janvier, M. Jebavy, L. Joensuu, H. Joerg, S. Jones, F.G.C. Jouet, J.P. Joyner, M.V. Juliusson, G. Jürgens, H. Kalayoglu-Besisik, S. Kalman, N. Kalmanti, M. Kansoy, S. Kansu, E. Kanz, L. Karianakis, G. Kernéis, Y. Khalifeh, O. Khomenko, V. Kienast, J. Killick, S. Kirchner, H.H. Klingebiel, T. Knauf, W. Koenigsmann, M. Koistinen, P. Koivunen, E. Kolb, H.-J. Kolbe, K. Koller, E. Komarnicki, M. Koscielniak, E. Kovacsovics, T. Kowalczyk, J.R. Koza, V. Kozak, T. Kugler, J. Kuliczkowski, K. Kvaloy, S. Labar, B. Laciura, P. Palacios, J.J.L. Lakota, J. Lambertenghi, D.G. Lange, A. Lanza, F. Isasti, R.L. Lauria, F. Le Moine, F. Leblond, V. Lelli, G. Lenhoff, S. Leon, L.A. Leoncini-Franscini, L. Leone, G. Leoni, P. Levis, A. Leyvraz, S. Liberati, M. Link, H. Linkesch, W. Liso, V. Lisukov, I.A. Littlewood, T. Ljungman, P. Locatelli, F. Losonczy, H. Lotz, J.-P. Ludwig, H. Lukac, J. Lutz, D. Macchia, P. Madrigal, A. Maiolino, A. Majolino, I. Eloy-García, J.M. Malesevic, M. Mandelli, F. Marc, A. Marcus, R. Marianska, B. Markuljak, I. Marsh, J.C.W. Martelli, M.F. Marti Tutusaus, J.M. Martin, S. Martin, M. Martinelli, G. Martínez-Rubio, A.M. Martoni, A. Maschan, A. Maschmeyer, G. Masszi, T. Mazza, P. McCann, S. Meier, C.R. Messina, C. Mettivier, V. Metzner, B. Michallet, M. Michieli, M. Michon, J. Milligan, D.W. Milone, J.H. Giuseppe, G.M. Minigo, H. Mistrik, M. Moicean, A.D. Monfardini, S. Montserrat, E. Moraleda Jimenez, J.M. Morales-Lazaro, A. Morandi, S. Morra, E. Mufti, G.J. Musso, M. Nagler, A. Nalli, G. Naparstek, E. Narni, F. Nenadov-Beck, M. Neubauer, A. Newland, A.C. Niederwieser, D. Niethammer, D. Noens, L.A. Nousiainen, T. Novik, A. Novitzky, N. Occhini, D. Odriozolas, J. Ojanguren, J.M. O’meara, A. Onat, H. Orchard, K. Ortega, J.J. Osieka, R. Ossenkoppele, G.J. Othman, B. Ovali, E. Ozcebe, O.I. Ozerkan, K. Ozturk, A. Papatryfonos, A. Parker, J.E. Pastore, M. Patrone, F. Patton, N. Pejin, D. Peñarrubia, M.J. Equiza, E.P. Peschel, C. Pession, A. Pigaditou, A. Pignon, B. Pihkala, U. Pimentel, P. Pitini, V. Podoltseva, E. Pogliani, E.M. Anna, A.P. Porta, F. Potter, M. Powles, R. Prentice, G.H. Pretnar, J. Ptushkin, V. Quarta, G. Reiter, A. Remes, K. Reykdal, S. Santasusana, J.M.R. Rifón, J. Rio, B. Rizzoli, V. Robak, T. Robinson, A.J. Rodeghiero, F. Rodríguez Fernández, J.M. Rombos, Y. Romeril, K.R. Rosenmayr, A. Rossi, J.F. Rosti, G. Rotoli, B. Rowe, J.M. Russell, N.H. Ryzhak, O. Rzepecki, P. Saglio, G. Salwender, H. Samonigg, H. Santoro, A. Sanz, M.A. Sayer, H.G. Scanni, A. Schaafsma, M.R. Schaefer, U.W. Schanz, U. Schattenberg, A. Schey, S.A.M. Schlimok, G. Schmoll, H.-J. Schots, R. Schouten, H. Schwarer, A.P. Schwerdtfeger, R. Scimè, R. Segel, E. Seger, R. Selleslag, D. Serban, M. Shamaa, S. Shaw, P.J. Siegert, W. Siena, S. Sierra, J. Simonsson, B. Singer, C.R.J. Sirchia, G. Skotnicki, A.B. Slavin, S. Snowden, J. Sotto, J.J. Tanyeli, A. Tedeschi, L. Tidefelt, U. Tissot, J.-D. Tobler, A. Tomas, J.F. Torres, J.P. Torres, G.A. Touraine, J.-L. Trneny, M. Uderzo, C. Unal, E. Unal, A. Undar, L. Urban, C. Van den Berg, H. van Marwijk, K.M. Vellenga, E. Venturini, M. Verdonck, L.F. Veys, P. Vilardell, J. Vinante, O. Visani, G. Vitek, A. Vivancos, P. Volpe, E. Vora, A. Vorlicek, J. Vowels, M. Vujic, D. Wachowiak, J. Wagner, T. Wahlin, A. Walewski, J. Wandt, H. Weissinger, F. Wijermans, P.W. Wiktor-Jedrzejczak, W. Will, A.M. Woell, E. Wörmann, B. Yaniv, I. Yesilipek, M.A. Yilmaz, U. Yong, A. Zachée, P. Zambelli, A. Zander, A.R. Zintl, F. Zoumbos, N.C. The Acute Leukemia Working Party (ALWP) of the European Cooperative Group for Blood Marrow Transplantation (EBMT)

Abstract

Several studies have compared bone marrow (BM) and peripheral blood (PB) as stem cell sources in patients receiving allografts, but the cell doses infused have not been considered, especially for BM. Using the ALWP/EBMT registry, we retrospectively studied 881 adult patients with acute myelocytic leukemia (AML), who received a non-T-depleted allogeneic BM (n = 515) or mobilized PB (n = 366) standard transplant, in first remission (CR1), from an HLA-identical sibling, over a 5-year period from January 1994. The BM cell dose ranged from 0.17 to 29 × 108/kg with a median of 2.7 × 108/kg. The PB cell dose ranged from 0.02 to 77 × 10 8/kg with a median of 9.3 × 108/kg. The median dose for patients receiving BM (2.7 × 108/kg) gave the greatest discrimination. In multivariate analyses, high-dose BM compared to PB was associated with lower transplant-related mortality (RR = 0.61; 95% CI, 0.39-0.98; P = .04), better leukemia-free survival (RR = 0.65; 95% CI, 0.46-0.91; P = .013), and better overall survival (RR = 0.64; 95% CI, 0.44-0. 92; P = .016). The present study in patients with AML receiving allografts in first remission indicates a better outcome with BM as compared to PB, when the dose of BM infused is rich. © 2003 by The American Society of Hematology.

Published
2003

9. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: A retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT)

Author

UCL - MD/MINT - Département de médecine interne, Aoudjhane, M., Labopin, M., Gorin, N.C., Shimoni, A., Ruutu, T., Kolb, H.-J., Frassoni, F., Boiron, J.M., Yin, J.L., Finke, J., Shouten, H., Blaise, D., Falda, M., Fauser, A.A., Esteve, J., Polge, E., Slavin, S., Niederwieser, D., Nagler, A., Rocha, Vanderson, Galiene, P., Petrini, M., Schlimok, G., Buzyn, A., Ovali, E., Gratwohl, A., Willemze, R., Bunjes, D., Goldman, J.M., Jacobsen, N., Gluckman, E., Schanz, U., Boogaerts, M.A., Ljungman, P., Montserrat, E., Bron, D., Potter, M., Bacigalupo, A., Powles, R., Rio, B., Kanz, L., Goldstone, A.H., Remes, K., Greinix, H.T., Davies, J.M., Mandelli, F., Cahn, J.Y., Ferrant, Augustin, Brinch, L., Fernández-Ranada, J.M., Torres Gomez, A., Verdonck, L.F., Baccarani, M., Iriondo, A., Franklin, I., Rizzoli, V., Cornelissen, J.J., Van den Berg, H., Cordonnier, C., Harousseau, J.L., Barnard, D.L., Littlewood, T., Horst, H.A., McCann, S., Schaefer, U.W., Sierra, J., Chapuis, B., Leblond, V., Guilhot, F., Lambertenghi Deliliers, G., Simonsson, B., Reiffers, J., Sotto, J.J., Gastl, G., Bay, J.O., Jackson, G.L., García-Conde, J., Lenhoff, S., Alessandrino, E.P., Majolino, I., Izzi, T., Brune, M., Pimentel, P., Siegert, W., Morra, E., Hertenstein, B., Hoelzer, D., Coser, P., Abecasis, M., Labar, B., Burnett, A.K., Bosi, A., Leone, G., Linkesch, W., Schwerdtfeger, R., Lauria, F., UCL - MD/MINT - Département de médecine interne, Aoudjhane, M., Labopin, M., Gorin, N.C., Shimoni, A., Ruutu, T., Kolb, H.-J., Frassoni, F., Boiron, J.M., Yin, J.L., Finke, J., Shouten, H., Blaise, D., Falda, M., Fauser, A.A., Esteve, J., Polge, E., Slavin, S., Niederwieser, D., Nagler, A., Rocha, Vanderson, Galiene, P., Petrini, M., Schlimok, G., Buzyn, A., Ovali, E., Gratwohl, A., Willemze, R., Bunjes, D., Goldman, J.M., Jacobsen, N., Gluckman, E., Schanz, U., Boogaerts, M.A., Ljungman, P., Montserrat, E., Bron, D., Potter, M., Bacigalupo, A., Powles, R., Rio, B., Kanz, L., Goldstone, A.H., Remes, K., Greinix, H.T., Davies, J.M., Mandelli, F., Cahn, J.Y., Ferrant, Augustin, Brinch, L., Fernández-Ranada, J.M., Torres Gomez, A., Verdonck, L.F., Baccarani, M., Iriondo, A., Franklin, I., Rizzoli, V., Cornelissen, J.J., Van den Berg, H., Cordonnier, C., Harousseau, J.L., Barnard, D.L., Littlewood, T., Horst, H.A., McCann, S., Schaefer, U.W., Sierra, J., Chapuis, B., Leblond, V., Guilhot, F., Lambertenghi Deliliers, G., Simonsson, B., Reiffers, J., Sotto, J.J., Gastl, G., Bay, J.O., Jackson, G.L., García-Conde, J., Lenhoff, S., Alessandrino, E.P., Majolino, I., Izzi, T., Brune, M., Pimentel, P., Siegert, W., Morra, E., Hertenstein, B., Hoelzer, D., Coser, P., Abecasis, M., Labar, B., Burnett, A.K., Bosi, A., Leone, G., Linkesch, W., Schwerdtfeger, R., and Lauria, F.

Abstract

Results of reduced intensity conditioning regimen (RIC) in the HLA identical haematopoietic stem cell transplantation (HSCT) setting have not been compared to those after myeloablative (MA) regimen HSCT in patients with acute myeloblastic leukaemia (AML) over 50 years of age. With this aim, outcomes of 315 RIC were compared with 407 MA HSCT recipients. The majority of RIC was fludarabine-based regimen associated to busulphan (BU) (53%;) or low-dose total body irradiation (24%). Multivariate analyses of outcomes were used adjusting for differences between both groups. The median follow-up was 13 months. Cytogenetics, FAB classification, WBC count at diagnosis and status of the disease at transplant were not statistically different between the two groups. However, RIC patients were older, transplanted more recently, and more frequently with peripheral blood allogeneic stem cells as compared to MA recipients. In multivariate analysis, acute GVHD (II -IV) and transplant-related mortality were significantly decreased (P=0.01 and P<10-4, respectively) and relapse incidence was significantly higher (P=0.003) after RIC transplantation. Leukaemia-free survival was not statistically different between the two groups. These results may set the grounds for prospective trials comparing RIC with other strategies of treatment in elderly AML. © 2005 Nature Publishing Group All rights reserved.

Published
2005

10. INTERFERON ALFA-2A AS COMPARED WITH CONVENTIONAL CHEMOTHERAPY FOR THE TREATMENT OF CHRONIC MYELOID LEUKEMIA

Author

Tura, S, Baccarani, M, Zuffa, E, Russo, D, Zaccaria, A, Fiacchini, M, Testoni, N, Zamagni, M, Martinelli, G, Damiani, D, Michieli, M, Fowst, C, Holdener, E, Specchia, G, Liso, V, Morra, E, Bernasconi, C, Alimena, G, Mandelli, F, Leoni, P, Danieli, G, Nosari, A, Decataldo, F, Majolino, I, Caronia, F, Liberati, A, Grignani, F, Tabilio, A, Martelli, M, Paolino, F, Resegotti, L, Ditucci, A, Broccia, G, Leoni, F, Ciolli, S, Luciano, L, Rotoli, B, Perricone, R, Cajozzo, A, Montuoro, A, Delaurenzi, A, Volpe, E, Demilio, A, Battista, R, Capucci, A, Izzi, T, Scapoli, G, Castoldi, G, Lombardo, M, Torlontano, G, Landolfi, R, Leone, G, Delfini, C, Sparaventi, G, Papineschi, F, Spremolla, G, Risso, M, Marmont, A, Dini, D, Diprisco, U, Mangoni, L, Rizzoli, V, Girino, M, Ascari, E, Bodenizza, C, Carotenuto, M, Difrancesco, A, Quaglino, D, Nardelli, S, Ciccone, F, Miraglia, E, Debiase, R, Gallo, E, Pileri, A, Rambaldi, A, Barbui, T, Morandi, S, Bianchini, E, Derosa, C, Cimino, R, Ronca, F, Nobile, F, Cantonetti, M, Papa, G, Gallamini, A, Buffa, F, Musolino, C, Squadrito, G, Capaldi, A, Giovannelli, E, Pinotti, G, Venco, A, Zagonel, V, Pinto, A, Gentilini, I, Coser, P, Guglielmo, P, Cacciola, E, Pizzuti, M, Ricciuti, F, Fanin, R, Criscuolo, D, and Montefusco, E

Subjects
Settore MED/06 - Oncologia Medica, CHRONIC MYELOGENOUS LEUKEMIA, BONE-MARROW TRANSPLANTATION, THERAPY, Settore MED/15 - Malattie del Sangue
Published
1994

11. EVALUATING SURVIVAL AFTER ALLOGENEIC BONE-MARROW TRANSPLANT FOR CHRONIC MYELOID-LEUKEMIA IN CHRONIC PHASE - A COMPARISON OF TRANSPLANT VERSUS NO-TRANSPLANT IN A COHORT OF 258 PATIENTS 1ST SEEN IN ITALY BETWEEN 1984 AND 1986

Author

Tura, S, Fanin, R, Russo, D, Zuffa, F, Fiacchini, M, Baccarani, M, Testoni, N, Zamagni, D, Zaccaria, A, Damiani, D, Michieli, M, Alimena, G, Montefusco, E, Mandelli, F, Morra, E, Bernasconi, C, Guglielmi, P, Cacciola, E, Battista, R, Dini, E, Specchia, G, Liso, V, Majolino, I, Caronia, F, Leoni, P, Danieli, G, Nosari, A, Decataldo, F, Paolino, F, Resegotti, L, Comotti, B, Barbui, T, Scapoli, G, Castoldi, G, Prossomariti, L, Montuori, R, Riccardi, A, Ascari, E, Landolfi, R, Bizzi, B, Lombardo, M, Torlontano, G, Leoni, F, Ferrini, P, Sparaventi, G, Delfini, C, Papineschi, F, Spremolla, G, Broccia, G, Nardelli, S, Ciccone, F, Deriu, L, Miraglia, E, Debiase, R, Bodenizza, C, Carotenuto, M, Rotondo, S, Gentilini, I, Coser, P, Capucci, A, Izzi, T, Luciano, L, Rotoli, B, Iacopino, P, Nobile, F, Cantonetti, M, Papa, G, Pinotti, G, Sala, G, Foa, P, Maiolo, M, Avanzini, P, Gobbi, F, Dore, F, Pardini, S, Ambrosetti, A, Perona, G, Dini, D, Liberati, A, Martelli, M, Grignani, F, Montuoro, A, Delaurenzi, A, Gallo, E, Pileri, A, Gallamini, A, Buffa, F, Abbadessa, A, Bruzzese, L, Derosa, C, Cimino, R, Mangoni, L, Rizzoli, V, Pizzuti, M, Ricciuti, F, Galieni, P, Dispensa, E, Zagonel, V, Pinto, A, Musolino, C, Squadrito, G, Perricone, R, Cajozzo, A, Morandi, S, Bianchini, E, Miliani, A, Monaco, M, Difrancesco, A, Quaglino, D, Rosti, G, Marangolo, M, Pasini, F, Diperri, T, Aglietta, M, and Gavosto, F

Subjects
RISK, Settore MED/06 - Oncologia Medica, CHRONIC MYELOGENOUS LEUKEMIA, CHRONIC GRANULOCYTIC-LEUKEMIA, CHEMOTHERAPY, IRRADIATION, RELAPSE, Settore MED/15 - Malattie del Sangue
Published
1993

12. PROGNOSTIC FACTORS IN CHRONIC MYELOID-LEUKEMIA - RELATIONSHIP WITH INTERFERON AND BONE-MARROW TRANSPLANTATION

Author

Tura, S, Russo, D, Fanin, R, Zuffa, E, Patriarca, F, Fiacchini, M, Baccarani, M, Testoni, N, Zamagni, M, Zaccaria, A, Montefusco, E, Alimena, G, Meloni, G, Mandelli, F, Damiani, D, Michieli, M, Silvestri, F, Virgolini, L, Criscuolo, D, Fowst, C, Holdener, E, Specchia, G, Liso, V, Morra, E, Bernasconi, C, Demilio, A, Battista, R, Ditucci, A, Broccia, G, Majolino, I, Caronia, F, Luciano, L, Rotoli, B, Leoni, P, Bodenizza, C, Carotenuto, M, Rotondo, S, Nosari, A, Decataldo, F, Montuoro, A, Delaurenzi, A, Liberati, A, Tabilio, A, Martelli, M, Rambaldi, A, Barbui, T, Leoni, F, Ciolli, S, Ronca, F, Nobile, F, Paolino, F, Resegotti, L, Papineschi, F, Spremolla, G, Landolfi, R, Leone, G, Volpe, E, Mangoni, L, Rizzoli, V, Capucci, A, Izzi, T, Gentilini, I, Coser, P, Gallo, E, Pileri, A, Cantonetti, M, Papa, G, Dini, D, Diprisco, U, Morandi, S, Bianchini, E, Pinotti, G, Venco, A, Zagonel, V, Pinto, A, Capaldi, A, Giovannelli, E, Pizzuti, M, Ricciuti, F, Ambrosetti, A, Perona, G, Perricone, R, Cajozzo, A, Lombardo, M, Torlontano, G, Delfini, C, Lucarelli, G, Girino, M, and Ascari, E

Subjects
CHRONIC MYELOID LEUKEMIA, PROGNOSIS, INTERFERON Addresses, Settore MED/06 - Oncologia Medica, BONE MARROW TRANSPLANTATION, Settore MED/15 - Malattie del Sangue
Published
1993

13. KARYOTYPIC CONVERSION BY INTERFERON AS PREPARATIVE TREATMENT FOR AUTOLOGOUS BMT IN PH POSITIVE CML

Author

Gobbi, M, Tura, S, Russo, D, Zuffa, E, Patriarca, F, Fiacchini, M, Baccarani, M, Montefusco, E, Meloni, G, Mandelli, F, Zamagni, M, Testoni, N, Zaccaria, A, Fanin, R, Damiani, D, Michieli, M, Criscuolo, D, Fowst, C, Holdener, E, Specchia, G, Liso, V, Demilio, A, Battista, R, Ditucci, A, Broccia, G, Bodenizza, C, Carotenuto, M, Rotondo, G, Ambrosetti, A, Perona, G, Majolino, I, Caronia, F, Luciano, L, Rotoli, B, Morra, E, Bernasconi, C, Rambaldi, A, Barbui, T, Ronco, F, Nobile, F, Leoni, P, Nosari, A, Decataldo, F, Montuoro, A, Delaurenzi, A, Camillo, S, Gentilini, I, Coser, P, Dini, D, Diprisco, U, Papineschi, F, Spremolla, G, Liberati, A, Grignani, G, Tabilio, A, Martelli, M, Pardini, S, Longinotti, M, Mangoni, L, Rizzoli, V, Galieni, P, Dispensa, E, Abbadessa, A, Bruzzese, L, Leoni, F, Ciolli, S, Cantonetti, M, Papa, G, Landolfi, R, Leone, G, Gallo, E, Pileri, A, Zagonel, V, Pinto, A, Volpe, E, Difrancesco, A, Quaglino, D, Avanzini, P, Gobbi, F, Paolino, F, Resegotti, L, Saglio, G, Camaschella, C, Mazza, U, Pinotti, G, Venco, G, Capucci, A, Izzi, T, Morandi, S, Bianchini, E, Scapoli, G, Monaco, M, Pizzuti, M, Ricciuti, F, Capaldi, A, and Giovannelli, E

Subjects
INTERFERON, AUTOLOGOUS BMT, Settore MED/06 - Oncologia Medica, KARYOTYPIC CONVERSION, Settore MED/15 - Malattie del Sangue, PH+CML
Published
1993

14. TREATMENT OF PH-POSITIVE CHRONIC MYELOID-LEUKEMIA WITH ALPHA-INTERFERON (ROFERON-A) - THE ITALIAN COOPERATIVE STUDY-GROUP EXPERIENCE

Author

Tura, S, Russo, D, Zuffa, E, Fanin, R, Patriarca, F, Fiacchini, M, Baccarani, M, Testoni, N, Zamagni, M, Zaccaria, A, Montefusco, E, Alimena, G, Meloni, G, Mandelli, F, Damiani, D, Michieli, M, Criscuolo, D, Fowst, C, Holdener, E, Specchia, G, Liso, V, Morra, E, Bernasconi, C, Demilio, A, Battista, R, Ditucci, A, Broccia, G, Maiolino, I, Caronia, F, Luciano, L, Rotoli, B, Leoni, P, Danieli, G, Bodenizza, C, Carotenuto, M, Rotondo, S, Nosari, A, Decataldo, F, Montuoro, A, Delaurenzi, A, Camillo, S, Liberati, A, Grignani, F, Tabilio, A, Rambaldi, A, Barbui, T, Leoni, F, Ciolli, S, Ronca, F, Nobile, F, Paolino, F, Resegotti, L, Papineschi, F, Spremolla, G, Landolfi, R, Leone, G, Volpe, E, Mangoni, L, Rizzoli, V, Capucci, A, Izzi, T, Scapoli, G, Castoldi, G, Gentilini, I, Coser, P, Gallo, E, Pileri, A, Cantonetti, M, Papa, G, Dini, D, Diprisco, U, Morandi, S, Bianchini, E, Pinotti, G, Venco, A, Zagonel, V, Pinto, A, Capaldi, A, Giovannelli, E, Pizzuti, M, Ricciuti, F, Ambrosetti, A, Perona, G, Perricone, R, Cajozzo, A, Lombardo, M, Torlontano, G, Delfini, C, Lucarelli, G, Girino, M, Ascari, E, Risso, M, Damasio, E, Martino, S, Pardini, S, Longinotti, M, Miraglia, E, Debiase, R, Nardelli, S, Ciccone, F, Galieni, P, Dispensa, E, Abbadessa, A, Bruzzese, L, Prossomariti, L, Cimino, R, Derosa, C, Gabbas, A, Francesco, S, Gallamini, A, Difrancesco, A, Quaglino, D, Musolino, C, Squadrito, G, Avanzini, P, Gobbi, F, Nuova, A, Emilia, R, Saglio, G, Aglietta, M, Camaschella, C, Mazza, M, Guglielmo, P, Cacciola, E, and Monaco, M

Subjects
CHRONIC MYELOID LEUKEMIA, PHILADELPHIA CHROMOSOME, INTERFERON AUTOLOGOUS BONE MARROW TRANSPLANT, Settore MED/06 - Oncologia Medica, Settore MED/15 - Malattie del Sangue
Published
1993

16. 'Minimal residual disease status in transplanted CML patients: low incidence of PCR positive cases among 48 disease-free subjects who received unmanipulated allogeneic bone marrow transplants'

Author

Guerrasio, A., Martinelli, G., Saglio, G., Rosso, C., Zaccaria, A., Rosti, G., Testoni, N., Ambrosetti, A., Izzi, T., Sessarego, M., Frassoni, F., Gasparini, Paolo, A., Guerrasio, G., Martinelli, G., Saglio, C., Rosso, A., Zaccaria, G., Rosti, N., Testoni, A., Ambrosetti, T., Izzi, M., Sessarego, F., Frassoni, and Gasparini, Paolo

Published
1992

17. Late taste disorders in bone marrow transplantation: clinical evaluation with taste solutions in autologous and allogeneic bone marrow recipients

Author

Mg, Marinone, Rizzoni D, Ferremi P, Giuseppe Rossi, Izzi T, and Brusotti C

Subjects
Adult, Male, Sucrose, Time Factors, Adolescent, Graft vs Host Disease, Middle Aged, Sodium Chloride, Quinidine, Transplantation, Autologous, Citric Acid, Cohort Studies, Solutions, Taste Disorders, Taste Threshold, Humans, Transplantation, Homologous, Female, Citrates, Bone Marrow Transplantation, Retrospective Studies
Abstract

The aim of this work was to determine the type and the significance of taste disorders in allogeneic bone marrow transplanted patients. In a retrospective study the taste threshold of a cohort of 15 allogeneic bone marrow transplanted patients, 4-51 months after transplantation (mean: 30.6 +/- 15.8), was compared to the taste threshold of 8 autologous bone marrow recipients, 4-48 months after transplantation (mean: 24.12 +/- 12.18), and to the taste threshold of a group of 20 consecutive normal subjects. Allogeneic bone marrow transplanted patients showed a significant hypogeusia for salt (Pearson's chi square p = 0.0002; Yates' correction p = 0.0007) and sour (Pearson's chi square p = 0.001; Yates' correction p = 0.008). No significant variations were observed for sweet and bitter. Autologous bone marrow recipients did not show any significant variation of taste acuity for sweet, salt or sour; a constant reduction of the taste threshold for bitter was observed, but the values were not significantly different from normal (Pearson's chi square p = 0.47; Yates' correction p = 0.83). So, late and selective taste disorders are observed in allogeneic bone marrow transplanted patients. Since the severity of the disorders is not strictly related to the severity of chronic oral G.V.H.D., taste analysis could discover the slightest, clinically undetectable cases of chronic oral G.V.H.D. The mechanism of immune aggression on the sensorial taste cells is poorly understood. Further trials are needed to define variations of taste acuity not only after allogeneic bone marrow transplantation, but also in systemic immune diseases.

Published
1991

23. CONFIRMATION AND IMPROVEMENT OF SOKAL PROGNOSTIC CLASSIFICATION OF PH+ CHRONIC MYELOID-LEUKEMIA - THE VALUE OF EARLY EVALUATION OF THE COURSE OF THE DISEASE

Author

Tura, S, Russo, D, Zuffa, E, Fiacchini, M, Baccarani, M, Testoni, N, Zamagni, D, Zaccaria, A, Fanin, R, Damiani, D, Michieli, M, Alimena, G, Montefusco, E, Mandelli, F, Morra, E, Bernasconi, C, Guglielmi, P, Cacciola, E, Battista, R, Dini, E, Specchia, G, Liso, V, Majolino, I, Caronia, F, Leoni, P, Danieli, G, Nosari, A, Decataldo, F, Paolino, F, Resegotti, L, Comotti, B, Barbui, T, Scapoli, G, Castoldi, G, Prossomariti, L, Montuori, R, Riccardi, A, Ascari, E, Landolfi, R, Bizzi, B, Lombardo, M, Torlontano, G, Leoni, F, Ferrini, P, Sparaventi, G, Lucarelli, G, Papineschi, F, Spremolla, G, Broccia, G, Nardelli, S, Ciccone, F, Deriu, L, Miraglia, E, Debiase, R, Bodenizza, C, Carotenuto, M, Rotondo, S, Gentilini, I, Coser, P, Capucci, A, Izzi, T, Luciano, L, Rotoli, B, Iacopino, P, Nobile, F, Cantonetti, M, Papa, G, Pinotti, G, Sala, G, Foa, P, Maiolo, M, Avanzini, P, Gobbi, F, Dore, F, Longinotti, M, Ambrosetti, A, Perona, G, Dini, D, Diprisco, U, Liberati, A, Martelli, M, Grignani, F, Montuoro, A, Delaurenzi, A, Gallo, E, Pileri, A, Gallamini, A, Buffa, F, Abbadessa, A, Bruzzese, L, Derosa, C, Cimino, R, Mangoni, L, Rizzoli, V, Pizzuti, M, Ricciuti, F, Galieni, P, Dispensa, E, Zagonel, V, Pinto, A, Musolino, C, Squadrito, G, Perricone, R, Cajozzo, A, Morandi, S, Bianchini, E, Miliani, A, Monaco, M, Difrancesco, A, Quaglino, D, Rosti, G, Marangolo, M, Pasini, F, Diperri, T, Aglietta, M, and Gavosto, F

Subjects
MARROW TRANSPLANTATION, CHRONIC MYELOCYTIC-LEUKEMIA, Settore MED/06 - Oncologia Medica, CHRONIC MYELOGENOUS LEUKEMIA, DURATION, SURVIVAL, CHRONIC PHASE, CHRONIC GRANULOCYTIC-LEUKEMIA, MULTIVARIATE-ANALYSIS, BCR BREAKPOINT, DIAGNOSIS, Settore MED/15 - Malattie del Sangue
Published
1991

27. 194 Myelodysplastic syndrome or leukemia developing after MDS treated by allogeneic bone marrow transplantation: Outcome of 90 adult patients

Author

Alessandrino, E.P., primary, Astori, C., additional, Van Lint, MT, additional, Bernasconi, P., additional, Arcese, W., additional, Polchi, P., additional, Di Bartolomeo, P., additional, Aversa, F., additional, Izzi, T., additional, Bandini, G., additional, Bosi, A., additional, Lambertenghi, G., additional, Locatelli, F., additional, Falda, M., additional, Iacopino, P., additional, and Bacigalupo, A., additional

Published
1997
Full Text
View/download PDF

28. Idarubicin in the Initial Treatment of Adults with Acute Lymphoblastic Leukemia: The Effect of Drug Schedule on Outcome

Author

Bassan, R., primary, Battista, R., additional, Corneo, G., additional, Rossi, G., additional, Lambertenghi-Deliliers, G., additional, Viero, P., additional, Rambaldi, A., additional, D'Emilio, A., additional, Neonat, M. G., additional, Pogliani, E., additional, Oriani, A., additional, Izzi, T., additional, Dinl, E., additional, and Barbui, T., additional

Published
1993
Full Text
View/download PDF

31. Minimal residual disease status in transplanted chronic myelogenous leukemia patients: Low incidence of polymerase chain reaction positive cases among 48 long disease-free subjects who received unmanipulated allogeneic bone marrow transplants

Author

Guerrasio, A., Martinelli, G., Giuseppe Saglio, Rosso, C., Zaccaria, A., Rosti, G., Testoni, N., Ambrosetti, A., Izzi, T., Sessarego, M., Frassoni, F., Gasparini, P., Chiamenti, A., Di Bartolomeo, P., and Pignatti, P. F.

Subjects
Adult, Male, Adolescent, Base Sequence, Bone Marrow Purging, Molecular Sequence Data, Remission Induction, Fusion Proteins, bcr-abl, Middle Aged, Polymerase Chain Reaction, Child, Preschool, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Humans, Transplantation, Homologous, Female, Philadelphia Chromosome, RNA, Messenger, RNA, Neoplasm, Child, Aged, Bone Marrow Transplantation, Follow-Up Studies
Abstract

Forty-eight long-term disease-free chronic myelogenous leukemia (CML) patients, who had received unmanipulated allogeneic bone marrow transplants (BMT) for eradication of the Philadelphia (Ph1)-positive clone were studied by polymerase chain reaction (PCR), using a very sensitive PCR procedure and very stringent criteria for preventing and revealing contamination. Nine patients (18%) were positive at the first PCR examination, but only one patient remained PCR positive four years after. However, a second PCR analysis performed on new bone marrow samples obtained at a median interval of 14 months (range 6-16) after the first specimen collection from six of nine originally positive cases, and from 16 of 39 originally negative cases, showed that only one of the six positive cases remained positive, whereas negativity was confirmed in all the originally negative patients. These data are evidence that the Ph1-positive clone is apparently completely eradicated in the majority of CML patients who survive disease-free long-term after an unmanipulated allogeneic BMT and that only sporadic cases remain PCR-positive four years post-BMT. The data also show that at least two sequential bone marrow samples for each patient must be analyzed before drawing conclusions regarding the stable persistence of BCR/ABL transcripts and the minimal residual disease status.

33. Reconstitution of T-cell receptor repertoire diversity following non-myeloablative allogeneic stem cell transplantation in an acute myeloid leukemia patient

Author

Almici C, Imberti L, Lanfranchi A, rosanna verardi, Bellinzoni M, Berta S, Izzi T, and Università degli Studi di Pavia

Subjects
Adult, Antigens, Differentiation, T-Lymphocyte, Male, Neutrophils, T-Lymphocytes, [PHYS.PHYS.PHYS-BIO-PH]Physics [physics]/Physics [physics]/Biological Physics [physics.bio-ph], MESH: Lymphocyte Subsets, Receptors, Antigen, T-Cell, [SDV.BC]Life Sciences [q-bio]/Cellular Biology, MESH: Neutrophils, Blood Transfusion, Autologous, MESH: Blood Transfusion, Autologous, MESH: Polymorphism, Genetic, [CHIM.CRIS]Chemical Sciences/Cristallography, Humans, [SDV.BBM]Life Sciences [q-bio]/Biochemistry, Molecular Biology, ComputingMilieux_MISCELLANEOUS, Polymorphism, Genetic, MESH: Humans, MESH: Adult, MESH: Receptors, Antigen, T-Cell, Lymphocyte Subsets, MESH: Male, Leukemia, Myeloid, Acute, [SDV.BBM.BS]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Biomolecules [q-bio.BM], MESH: T-Lymphocytes, MESH: Antigens, Differentiation, T-Lymphocyte, MESH: Stem Cell Transplantation, [INFO.INFO-BI]Computer Science [cs]/Bioinformatics [q-bio.QM], MESH: Leukemia, Myeloid, Acute, Stem Cell Transplantation
Abstract

International audience

34. bcr/abl chimeric transcript in patients in remission after marrow transplantation for chronic myeloid leukemia: Higher frequency of detection and slower clearance in patients grafted in advanced disease as compared to patients grafted in chronic phase

Author

Frassoni, F., Martinelli, G., Giuseppe Saglio, Sessarego, M., Podesta, M., Piaggio, G., Farabegoli, P., Zaccaria, A., Testoni, N., Remiddi, C., Bacigalupo, A., Di Bartolomeo, P., Angrilli, F., Falda, M., Locatelli, F., Izzi, T., Gottardi, E., and Guerrasio, A.

36. [Aggressive ulcerous stomatitis due to the herpes simplex virus in an allogeneic bone marrow transplant. A clinical case]

Author

Mg, Marinone, Paganelli C, Ferremi P, Giuseppe Rossi, and Izzi T

Subjects
Adult, Male, Stomatitis, Herpetic, Leukemia, Myeloid, Acute, Postoperative Complications, Skin Neoplasms, Acyclovir, Graft vs Host Disease, Humans, Transplantation, Homologous, Combined Modality Therapy, Melanoma, Bone Marrow Transplantation
Abstract

Aggressive ulcerative HSV stomatitis was observed in a patient 10 months after allogeneic bone marrow transplantation. The patient was affected by acute myeloid leukemia (LMA) in second remission and, after bone marrow transplantation, supported a severe graft versus host disease. Intravenous acyclovir was administered during 22 days and ulcerative stomatitis completely healed.

38. Early splenectomy and polychemotherapy versus polychemotherapy alone in chronic myeloid leukemia

Author

Baccarani, Michele, primary, Corbelli, Giovanna, additional, Tura, Sante, additional, Tura, S., additional, Corbelli, G., additional, Fiacchini, M., additional, Gobbi, M., additional, Gugliotta, L., additional, Lauria, F., additional, Ricci, P., additional, Zaccaria, A., additional, Baccarani, M., additional, Mandelli, F., additional, Alimena, G., additional, Papa, G., additional, Annino, L., additional, Guglielmi, G., additional, Salinas, F., additional, Martelli, M.F., additional, Tonato, M., additional, Soldani, M., additional, De Sandre, G., additional, Cetto, G., additional, Pizzolo, G., additional, Perona, G., additional, De Cataldo, F., additional, Panzacchi, G., additional, Giustolisi, R., additional, Musso, R., additional, Raimondo, V., additional, Cacciola, E., additional, Cajozzo, A., additional, Di Marco, P., additional, Citarrella, P., additional, Porcellini, A., additional, Izzi, T., additional, Manna, A., additional, Lucarelli, G., additional, Ferrini, P.Rossi, additional, Leoni, F., additional, Salti, F., additional, Bosisio, M., additional, Lanzi, E., additional, Dinelli, C.A., additional, Di Guglielmo, R., additional, Miliani, A., additional, Torlontano, G., additional, Geraci, L., additional, Palka, G.D., additional, Bruzzese, L., additional, Abbadessa, A., additional, Nappi, G., additional, Rizzoli, V., additional, Delsignore, A., additional, Sansoni, P., additional, Carnevali, C., additional, Bonati, A., additional, Quarantelli, C., additional, Monjardini, S., additional, Bajetta, E., additional, Buzzoni, R., additional, Broccia, G., additional, Alberti, A., additional, Magro, S., additional, Battista, R., additional, Barbui, T., additional, Dini, E., additional, Grignani, F., additional, Liberati, M., additional, and Allegra, A., additional

Published
1981
Full Text
View/download PDF

40. How should we describe complications and stratify error in the treatment of facial fractures? A systematic review of the literature.

Author

Al-Izzi T and Breeze J

Subjects
Humans, Emergency Service, Hospital, Skull Fractures surgery
Abstract

Oral and maxillofacial (OMFS) facial fractures account for approximately 5%-10% of presentations to emergency departments in the UK. Although most trauma is treated operatively, different methods of surgery exist for the same clinical presentation and non- surgical management is in some cases appropriate. Analysis of patient morbidity is an essential component of clinical governance in surgery. OMFS units in the UK should hold regular morbidity and mortality (M&M) meetings, but no consensus exists for which cases should be discussed. For example, most units focus only on cases treated surgically, primarily unexpected returns to theatre. Finally, there is no agreed structure for describing how complications occur and a focus on terms such as error. The aim of this review is to help inform which patients should be discussed in M&M meetings based on existing scoring systems. A systematic review of the literature has been undertaken using the Preferred Reporting in Systematic Reviews and Meta-Analysis methodology. Databases searched were PubMed and Science Direct. Eleven unique papers and a companion article met the criteria and were analysed. Many M&M classification systems exist, but these systems are unsuited for maxillofacial purposes. There is a need for a novel system which is tailored to the specialty., (Crown Copyright © 2022. Published by Elsevier Ltd. All rights reserved.)

Published
2022
Full Text
View/download PDF

41. Prospects for ultraviolet A1 phototherapy as a treatment for chronic cutaneous graft-versus-host disease.

Author

Calzavara Pinton P, Porta F, Izzi T, Venturini M, Capezzera R, Zane C, and Notarangelo LD

Subjects
Adult, Bone Marrow Transplantation methods, Child, Child, Preschool, Female, Humans, Immunosuppressive Agents adverse effects, Immunosuppressive Agents therapeutic use, Leukemia surgery, Male, Middle Aged, Prospective Studies, Transplantation, Homologous, Treatment Outcome, Graft vs Host Disease complications, Lichenoid Eruptions etiology, Lichenoid Eruptions therapy, PUVA Therapy methods, Scleroderma, Localized etiology, Scleroderma, Localized therapy
Abstract

Background and Objectives: Standard or investigative immunosuppressive therapies for cutaneous chronic graft-versus-host disease (GVHD) may prove not only ineffective but also cause serious adverse effects. Repeated exposure of the skin to ultraviolet radiation in the wavelength range 340-400 nm (so-called ultraviolet A1) was recently reported to have a strong local (intracutaneous) immunomodulatory activity. This study was undertaken to evaluate efficacy and safety of this phototherapy., Design and Methods: Nine patients with cutaneous (4 lichenoid and 5 sclerodermoid) GVHD and mild or no other organ involvement were enrolled. All patients had developed serious drug toxicity and/or opportunistic infections. Phototherapy was administered three times a week., Results: Complete remission was seen in 5 (2 lichenoid and 3 sclerodermoid) cases and a partial improvement in 4 (2 lichenoid and 2 sclerodermoid) after having received 15.8+/-3.8 (lichenoid GVHD) or 21.6+/-8.0 (sclerodermoid GVHD) sessions of phototherapy. Adverse effects were not registered. At follow-up (range: 6-25 months), two patients with sclerodermoid lesions relapsed after 5 months but responded to another treatment cycle. Patients with lichenoid GVHD showed relapses within one month and prolonged maintenance phototherapy was needed. Problems of drug toxicity and opportunistic infections improved as phototherapy allowed the reduction or interruption of systemic drug therapies., Interpretation and Conclusions: Ultraviolet A1 phototherapy may be considered as an appropriate therapeutic approach for sclerodermoid GVHD with no or mild involvement of internal organs. Patients with lichenoid GVHD should be treated only if they develop serious adverse effects to immunosuppressive therapies and opportunistic infections because of the carcinogenic hazard of high cumulative doses of ultraviolet A1 radiation.

Published
2003

42. Reconstitution of T-cell receptor repertoire diversity following non-myeloablative allogeneic stem cell transplantation in an acute myeloid leukemia patient.

Author

Almici C, Imberti L, Lanfranchi A, Verardi R, Bellinzoni M, Berta S, and Izzi T

Subjects
Adult, Antigens, Differentiation, T-Lymphocyte chemistry, Blood Transfusion, Autologous, Humans, Male, Neutrophils metabolism, Polymorphism, Genetic, Receptors, Antigen, T-Cell immunology, T-Lymphocytes chemistry, Leukemia, Myeloid, Acute immunology, Leukemia, Myeloid, Acute metabolism, Lymphocyte Subsets, Receptors, Antigen, T-Cell chemistry, Stem Cell Transplantation methods, T-Lymphocytes immunology
Published
2002

43. Fractionated cyclophosphamide added to the IVAP regimen (idarubicin-vincristine-L-asparaginase-prednisone) could lower the risk of primary refractory disease in T-lineage but not B-lineage acute lymphoblastic leukemia: first results from a phase II clinical study.

Author

Bassan R, Pogliani E, Lerede T, Fabris P, Rossi G, Morandi S, Casula P, Lambertenghi-Deliliers G, Vespignani M, Izzi T, Coser P, Corneo G, and Barbui T

Subjects
Adolescent, Adult, Aged, Asparaginase administration & dosage, Burkitt Lymphoma drug therapy, Burkitt Lymphoma prevention & control, Female, Humans, Idarubicin administration & dosage, Leukemia-Lymphoma, Adult T-Cell drug therapy, Leukemia-Lymphoma, Adult T-Cell prevention & control, Male, Middle Aged, Precursor Cell Lymphoblastic Leukemia-Lymphoma prevention & control, Prednisolone administration & dosage, Vincristine administration & dosage, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Cyclophosphamide administration & dosage, Precursor Cell Lymphoblastic Leukemia-Lymphoma drug therapy
Abstract

Background and Objective: In a prior study, primary resistant acute lymphoblastic leukemia (RES-ALL) was observed in 11 of 176 (6%) adult patients treated with a four drug regimen (IVAP), its incidence being higher in T-cell or Philadelphia (Ph) chromosome/BCR-ABL rearrangement positive ALL cases with a blast cell count >25x10(9)/L (RES-ALL rate 19%, p=0.04). Aiming to minimize this percentage of resistant disease, fractionated cyclophosphamide (f-CY) was then added to the IVAP regimen., Design and Methods: Study 08-96 was a prospective, collaborative phase II trial carried out at eight general hospital centers specialized in the care of hematologic malignancies. Historical IVAP-treated patients served as a retrospective control group. All consecutive, untreated patients (>15 years) with a diagnosis of ALL or advanced-stage lymphoblastic lymphoma (LBL) were eligible. RES-ALL was defined as the persistence of >5% ALL cells in the bone marrow 28-40 days after the start of the IVAP regimen (idarubicin 10 mg/m(2)/d on days 1 and 2; vincristine 2 mg on days 1, 8 and 15; L-asparaginase 6,000 U/m(2) on alternate days 3 6 from day 8; prednisone 60 mg/m(2)/d on days 1-21). In the new study, two f-CY schedules were sequentially adopted: CY 150 or 75 mg/m(2)/bd, given for 4 consecutive days before IVAP (f-CY 1200 or 600, expressing total CY dose in mg/m(2))., Results: Eighty-eight patients were evaluable (age range 15-74 years, blast count 0-240x10(9)/L, 14 T-lineage, 74 B-lineage, 13 Ph/BCR-ABL+). The first 39 patients received the f-CY 1200 schedule, 22 patients received f-CY 600, and the last 27 patients were not given any f-CY. These changes were dictated by the results of interim analyses of the f-CY groups (RES-ALL rate not reduced, myelotoxicity increased). Altogether, compared with the historical IVAP and no f-CY groups, the incidence of RES-ALL was not decreased by the addition of f-CY 1200/600 in B-lineage ALL, regardless of Ph/BCR-ABL expression and blast count. However, none of 14 T-ALL cases in the new study had RES-ALL (8 in f-CY groups, 5 of whom with >25x10(9)/L blast cells), compared to 5/39 (13%, overall) or 4/21 (19%, with >25x10(9)/L blast cells) among the control cases. Owing to small sample size, this difference was not statistically significant., Interpretation and Conclusions: This preliminary experience suggests that T-ALL may be more sensitive than B-lineage ALL to an early therapy including f-CY. The hypothesis could be tested in a larger clinical trial.

Published
1999

44. Induction-consolidation with an idarubicin-containing regimen, unpurged marrow autograft, and post-graft chemotherapy in adult acute lymphoblastic leukaemia.

Author

Bassan R, Lerede T, Di Bona E, Rambaldi A, Rossi G, Pogliani E, Oriani A, D'Emilio A, Izzi T, Lambertenghi-Deliliers G, Corneo G, and Barbui T

Subjects
Adolescent, Adult, Asparaginase administration & dosage, Disease-Free Survival, Female, Humans, Idarubicin administration & dosage, Male, Middle Aged, Precursor Cell Lymphoblastic Leukemia-Lymphoma drug therapy, Prednisolone administration & dosage, Remission Induction, Risk Factors, Transplantation, Homologous, Treatment Outcome, Vincristine administration & dosage, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Bone Marrow Transplantation methods, Precursor Cell Lymphoblastic Leukemia-Lymphoma therapy
Abstract

Between 1991 and 1993 we conducted a collaborative trial in adult acute lymphoblastic leukaemia, introducing an idarubicin (IDA)-containing regimen for induction and early consolidation, and increasing consolidation intensity with an autologous bone marrow transplantation phase (ABMT, patients aged <51 years) followed by further chemotherapy for 12 weeks and low-dose maintenance for 6 months (ABMT patients) or 18 months. 96 patients were evaluable for antileukaemic response after induction with vincristine-prednisone-L-asparaginase plus cumulative IDA 36 or 20 mg/m2 (IVAP-1 and IVAP-2), and for disease-free survival (DFS) after a minimum follow-up >3.5 years with an off-therapy interval >1.5 years. The response rate was 44% (7/16) with IVAP-1 and 90% (72/80) with IVAP-2 (P=0.0001), due to regimen-related toxicities. Post-remission therapy was administered as planned to most cases but protocol violation was registered in some patients eligible to ABMT and post-graft chemotherapy. The 5-year disease-free survival (DFS) rate was 31%. Multivariate analysis indicated that DFS was improved in patients receiving a transplant (11 allogeneic, DFS 70%; 32 ABMT, 36%; 37 neither, 17%; P < 0.001) and was negatively affected by high-risk features such as blast cell count >25x10(9)/l, T-cell or mature B-cell immunophenotype, and t(9;22)/t(4;11) (all P values <0.05). The 5-year DFS rate was 54% for 26 patients with no high-risk factor, 26% for 35 patients with any one, and 6% for 18 patients with any two (P<0.005). IVAP-2 brought about a high complete response rate and post-remission treatment including ABMT was feasible and modestly toxic. In spite of the short post-graft chemotherapy phase, the long-term DFS rate was good in cases with no high-risk feature. However, because autografting may be redundant in the standard-risk category, its role requires further investigation for high-risk cases.

Published
1999
Full Text
View/download PDF

45. Granulocyte colony-stimulating factor (G-CSF, filgrastim) after or during an intensive remission induction therapy for adult acute lymphoblastic leukaemia: effects, role of patient pretreatment characteristics, and costs.

Author

Bassan R, Lerede T, Di Bona E, Rossi G, Pogliani E, Rambaldi A, Buelli M, Viero P, Rodeghiero F, Izzi T, Corneo G, and Barbui T

Subjects
Adolescent, Adult, Asparaginase administration & dosage, Cost-Benefit Analysis, Female, Filgrastim, Granulocyte Colony-Stimulating Factor economics, Humans, Idarubicin administration & dosage, Male, Middle Aged, Patient Selection, Precursor Cell Lymphoblastic Leukemia-Lymphoma economics, Prednisolone administration & dosage, Prospective Studies, Recombinant Proteins, Remission Induction methods, Treatment Outcome, Vincristine administration & dosage, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Granulocyte Colony-Stimulating Factor therapeutic use, Precursor Cell Lymphoblastic Leukemia-Lymphoma drug therapy
Abstract

An early intensive anthracycline therapy can improve therapeutic outcome in adult acute lymphoblastic leukaemia (ALL) but is usually associated with marked myelosuppressive effects and significant morbidity by infections. To reduce this risk, we employed granulocyte colony-stimulating factor (G-CSF, filgrastim 5 microg/kg/d) as an adjunct to a myelotoxic, 14-day long induction regimen with idarubicin-vincristine-L-asparaginase-prednisone (IVAP). Owing to changes in study design, patients received 'late' (n = 28) or 'early' (n = 37) G-CSF from days 15 or 4 of IVAP, respectively, until resolution of severe neutropenia. Study endpoints included time to recovery from neutropenic nadir, duration of neutropenia <0.5 x 10(9)/l, incidence of infectious complications, assessment of variables affecting G-CSF response, clinical outcome and costs. Sixty-five consecutive cases were evaluable. Patients in early G-CSF group recovered significantly faster from the neutropenic nadir (p < 0.002), contracted less infectious complications (p = 0.007), and required less intravenous antibiotic (p = 0.008) and antifungal (p = 0.002) medications. Although these reductions did not compensate for the increased G-CSF treatment cost, the overall supportive care cost was not significantly increased by early G-CSF. Interestingly, T-ALL phenotype (p = 0.02) and higher neutrophil presentation count (p = 0.03) were associated with a shorter neutropenic course even with late G-CSF. Early G-CSF may be a valid approach to mitigate chemotherapy-induced neutropenia of IVAP and other similarly myelosuppressive adult ALL regimens.

Published
1997
Full Text
View/download PDF

46. Analysis of chimerism after bone marrow transplantation using specific oligonucleotide probes.

Author

Casarino L, Carbone C, Capucci MA, Izzi T, and Ferrara GB

Subjects
Adolescent, Adult, Base Sequence, Genetic Markers, HLA Antigens genetics, Humans, Leukemia surgery, Middle Aged, Molecular Sequence Data, Oligonucleotide Probes, Polymerase Chain Reaction, Polymorphism, Restriction Fragment Length, Sibling Relations, Bone Marrow Transplantation, Chimera genetics, DNA, Neoplasm chemistry, Leukemia genetics
Abstract

DNA hybridization with synthetic oligonucleotide probes was used to follow 18 leukemia patients who received bone marrow transplantation from HLA-identical siblings. Five oligomers complementary to the tandem repetitive sequences of different hypervariable regions of human DNA were designed to produce simple restriction fragment length polymorphism patterns. Each probe hybridized to one or two bands in Hinf I-digested genomic DNA. Combined use of these probes enabled us to distinguish all sibling pairs. DNA analysis early post-transplant (15 days) detected donor-specific fragments in 14 of 18 subjects; two patients had a combination of recipient and donor fragments. Later post-transplant, (102-15 days), one of these two showed only recipient-specific fragments, and the other donor-specific fragments. These data are in accord with other markers of engraftment including cytogenetics and red blood cell phenotyping.

Published
1992

47. Minimal residual disease status in transplanted chronic myelogenous leukemia patients: low incidence of polymerase chain reaction positive cases among 48 long disease-free subjects who received unmanipulated allogeneic bone marrow transplants.

Author

Guerrasio A, Martinelli G, Saglio G, Rosso C, Zaccaria A, Rosti G, Testoni N, Ambrosetti A, Izzi T, and Sessarego M

Subjects
Adolescent, Adult, Aged, Base Sequence, Child, Child, Preschool, Female, Follow-Up Studies, Fusion Proteins, bcr-abl genetics, Humans, Leukemia, Myelogenous, Chronic, BCR-ABL Positive diagnosis, Leukemia, Myelogenous, Chronic, BCR-ABL Positive genetics, Male, Middle Aged, Molecular Sequence Data, Philadelphia Chromosome, Polymerase Chain Reaction, RNA, Messenger analysis, RNA, Neoplasm analysis, Remission Induction, Transplantation, Homologous, Bone Marrow Purging, Bone Marrow Transplantation, Leukemia, Myelogenous, Chronic, BCR-ABL Positive surgery
Abstract

Forty-eight long-term disease-free chronic myelogenous leukemia (CML) patients, who had received unmanipulated allogeneic bone marrow transplants (BMT) for eradication of the Philadelphia (Ph1)-positive clone were studied by polymerase chain reaction (PCR), using a very sensitive PCR procedure and very stringent criteria for preventing and revealing contamination. Nine patients (18%) were positive at the first PCR examination, but only one patient remained PCR positive four years after. However, a second PCR analysis performed on new bone marrow samples obtained at a median interval of 14 months (range 6-16) after the first specimen collection from six of nine originally positive cases, and from 16 of 39 originally negative cases, showed that only one of the six positive cases remained positive, whereas negativity was confirmed in all the originally negative patients. These data are evidence that the Ph1-positive clone is apparently completely eradicated in the majority of CML patients who survive disease-free long-term after an unmanipulated allogeneic BMT and that only sporadic cases remain PCR-positive four years post-BMT. The data also show that at least two sequential bone marrow samples for each patient must be analyzed before drawing conclusions regarding the stable persistence of BCR/ABL transcripts and the minimal residual disease status.

Published
1992

48. Late taste disorders in bone marrow transplantation: clinical evaluation with taste solutions in autologous and allogeneic bone marrow recipients.

Author

Marinone MG, Rizzoni D, Ferremi P, Rossi G, Izzi T, and Brusotti C

Subjects
Adolescent, Adult, Citrates, Citric Acid, Cohort Studies, Female, Graft vs Host Disease, Humans, Male, Middle Aged, Quinidine, Retrospective Studies, Sodium Chloride, Solutions, Sucrose, Taste Disorders diagnosis, Taste Disorders epidemiology, Taste Threshold, Time Factors, Transplantation, Autologous, Transplantation, Homologous, Bone Marrow Transplantation adverse effects, Taste Disorders etiology
Abstract

The aim of this work was to determine the type and the significance of taste disorders in allogeneic bone marrow transplanted patients. In a retrospective study the taste threshold of a cohort of 15 allogeneic bone marrow transplanted patients, 4-51 months after transplantation (mean: 30.6 +/- 15.8), was compared to the taste threshold of 8 autologous bone marrow recipients, 4-48 months after transplantation (mean: 24.12 +/- 12.18), and to the taste threshold of a group of 20 consecutive normal subjects. Allogeneic bone marrow transplanted patients showed a significant hypogeusia for salt (Pearson's chi square p = 0.0002; Yates' correction p = 0.0007) and sour (Pearson's chi square p = 0.001; Yates' correction p = 0.008). No significant variations were observed for sweet and bitter. Autologous bone marrow recipients did not show any significant variation of taste acuity for sweet, salt or sour; a constant reduction of the taste threshold for bitter was observed, but the values were not significantly different from normal (Pearson's chi square p = 0.47; Yates' correction p = 0.83). So, late and selective taste disorders are observed in allogeneic bone marrow transplanted patients. Since the severity of the disorders is not strictly related to the severity of chronic oral G.V.H.D., taste analysis could discover the slightest, clinically undetectable cases of chronic oral G.V.H.D. The mechanism of immune aggression on the sensorial taste cells is poorly understood. Further trials are needed to define variations of taste acuity not only after allogeneic bone marrow transplantation, but also in systemic immune diseases.

Published
1991

49. [Aggressive ulcerous stomatitis due to the herpes simplex virus in an allogeneic bone marrow transplant. A clinical case].

Author

Marinone MG, Paganelli C, Ferremi P, Rossi G, and Izzi T

Subjects
Acyclovir administration & dosage, Adult, Combined Modality Therapy, Graft vs Host Disease complications, Graft vs Host Disease therapy, Humans, Leukemia, Myeloid, Acute complications, Leukemia, Myeloid, Acute therapy, Male, Melanoma complications, Melanoma drug therapy, Postoperative Complications diagnosis, Postoperative Complications drug therapy, Skin Neoplasms complications, Skin Neoplasms drug therapy, Stomatitis, Herpetic diagnosis, Stomatitis, Herpetic drug therapy, Transplantation, Homologous, Bone Marrow Transplantation, Postoperative Complications etiology, Stomatitis, Herpetic transmission
Abstract

Aggressive ulcerative HSV stomatitis was observed in a patient 10 months after allogeneic bone marrow transplantation. The patient was affected by acute myeloid leukemia (LMA) in second remission and, after bone marrow transplantation, supported a severe graft versus host disease. Intravenous acyclovir was administered during 22 days and ulcerative stomatitis completely healed.

Published
1991

50. Fetal liver transplant in aplastic anemia and acute leukemia.

Author

Izzi T, Polchi P, Galimberti M, Delfini C, Moretti L, Porcellini A, Manna A, Sparaventi G, Giardini C, and Angelucci E

Subjects
Child, Child, Preschool, Female, Fetus, Freezing, Humans, Liver cytology, Liver embryology, Male, Pregnancy, Tissue Preservation, Anemia, Aplastic therapy, Leukemia, Lymphoid therapy, Leukemia, Myeloid, Acute therapy, Liver Transplantation
Published
1985

Catalog

Books, media, physical & digital resources
See catalog results